DE3380848D1 - Molecular cloning of the gene for human anti-haemophilic factor ix - Google Patents

Molecular cloning of the gene for human anti-haemophilic factor ix

Info

Publication number
DE3380848D1
DE3380848D1 DE8383304487T DE3380848T DE3380848D1 DE 3380848 D1 DE3380848 D1 DE 3380848D1 DE 8383304487 T DE8383304487 T DE 8383304487T DE 3380848 T DE3380848 T DE 3380848T DE 3380848 D1 DE3380848 D1 DE 3380848D1
Authority
DE
Germany
Prior art keywords
gene
molecular cloning
human anti
haemophilic factor
haemophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383304487T
Other languages
English (en)
Inventor
George Gow Brownlee
Kong Hong Choo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838312491A external-priority patent/GB8312491D0/en
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Application granted granted Critical
Publication of DE3380848D1 publication Critical patent/DE3380848D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE8383304487T 1982-08-04 1983-08-03 Molecular cloning of the gene for human anti-haemophilic factor ix Expired DE3380848D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8222485 1982-08-04
GB838312491A GB8312491D0 (en) 1983-05-06 1983-05-06 Genetic engineering

Publications (1)

Publication Number Publication Date
DE3380848D1 true DE3380848D1 (en) 1989-12-21

Family

ID=26283513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8383304487T Expired DE3380848D1 (en) 1982-08-04 1983-08-03 Molecular cloning of the gene for human anti-haemophilic factor ix

Country Status (4)

Country Link
EP (2) EP0316558A1 (de)
JP (2) JP2625412B2 (de)
DE (1) DE3380848D1 (de)
WO (1) WO1984000560A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
FR2564106B1 (fr) * 1984-05-09 1988-04-22 Transgene Sa Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
DE3684546D1 (de) * 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2600334B1 (fr) * 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
FR2650838A1 (fr) * 1989-08-09 1991-02-15 Transgene Sa Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO1998041240A1 (en) 1997-03-14 1998-09-24 The Children's Hospital Of Philadelphia Methods and compositions for use in gene therapy for treatment of hemophilia
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
SI1969127T2 (sl) 2005-12-21 2017-10-30 Cnj Holdings, Inc Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami
JP6050927B2 (ja) 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
EP2811017A2 (de) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylierter humaner Koagulationsfaktor IX
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
SG181496A1 (en) 2009-12-18 2012-07-30 Csl Ltd Method of purifying polypeptides
US20150307863A1 (en) 2012-11-20 2015-10-29 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins

Also Published As

Publication number Publication date
WO1984000560A1 (en) 1984-02-16
EP0107278B1 (de) 1989-11-15
JPS59501343A (ja) 1984-08-02
JP2625412B2 (ja) 1997-07-02
EP0316558A1 (de) 1989-05-24
JPH09173081A (ja) 1997-07-08
EP0107278A1 (de) 1984-05-02
JP2764034B2 (ja) 1998-06-11

Similar Documents

Publication Publication Date Title
DE3372971D1 (en) Controlling the molecular weight of polybutadiene
DE3380848D1 (en) Molecular cloning of the gene for human anti-haemophilic factor ix
GB2120537B (en) Wheelchair
GB8304041D0 (en) Vaporizers
AU567683B2 (en) Highly purified human anti-hemophilic factor
GB8325627D0 (en) Therapeutic compositions
DE3570188D1 (en) Apparatus for the treatment of plasma
PH19156A (en) Dihydrocyclosporin d in the treatment of multiple sclerosis
ZA859008B (en) The treatment of tumors in mammals
GB8317357D0 (en) Therapeutic composition
EP0091723A3 (en) Transposable cloning vector
GB2129905B (en) Set of angle brackets
GB2120735B (en) Nebulizers
PT83137A (en) Process for the preparation of cardiotonic heterocyclocarbonyl- and acetyl-thiazolones
DE3272384D1 (en) Medicinal composition for the treatment of certain neuroviroses
GB2123822B (en) The preparations of indoles
GB8411749D0 (en) Oxygen therapy
AU562962B2 (en) Molecular cloning and characterisation of the gene sequence coding for human relaxin
GR3000306T3 (en) Composition for the treatment of infections
PT83528A (en) Process for the preparation of cardiotonic aroylthiazolones
PH23182A (en) Cardiotonic alkanoylthiazolones
ZA853759B (en) Tetrahydronaphthalenols for the treatment of hypertension
EP0190219A4 (de) Zusammensetzung zur behandlung von haemorroiden.
ZW21283A1 (en) The treatment of ferromanganese
ZA837183B (en) The treatment of ferromanganese

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BRITISH TECHNOLOGY GROUP LTD., LONDON, GB

8328 Change in the person/name/address of the agent

Free format text: DEUFEL, P., DIPL.-WIRTSCH.-ING.DR.RER.NAT. HERTEL, W., DIPL.-PHYS. RUTETZKI, A., DIPL.-ING.UNIV. RUCKER, E., DIPL.-CHEM. UNIV. DR.RER.NAT. HUBER, B., DIPL.-BIOL. DR.RER.NAT. BECKER, E., DR.RER.NAT., 80331 MUENCHEN KURIG, T., DIPL.-PHYS., 83022 ROSENHEIM STEIL, C., DIPL.-ING., PAT.-ANWAELTE, 80331 MUENCHEN